• BioXcel Therapeutics entered voluntary Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware to run a court-supervised asset sale.
• Teva signed an asset sale agreement to act as stalking-horse bidder for substantially all assets, including IGALMI and a pending BXCL501 sNDA.
• The company secured a USD 19 million debtor-in-possession financing commitment from existing secured lenders to fund operations during the process.
• IGALMI remains commercially available; supply and patient support are expected to continue in the ordinary course.
• The BXCL501 sNDA for potential at-home use has a PDUFA date of Nov. 14, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280600PRIMZONEFULLFEED9817546) on August 28, 2026, and is solely responsible for the information contained therein.